MedTrace Logo

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy

NCT04695327 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-03-06

No results posted yet for this study

Summary

This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.

Conditions

Interventions

BIOLOGICAL

TILT-123

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

Sponsors & Collaborators

  • TILT Biotherapeutics Ltd.

    lead INDUSTRY

Principal Investigators

  • Katriina Peltola, MD, PhD · Helsinki University Central Hospital

  • Tuomo Alanko, MD, PhD · Docrates Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-11
Primary Completion
2025-09-03
Completion
2025-09-03

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04695327 on ClinicalTrials.gov